Navigation Links
goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit
Date:1/11/2012

SAN FRANCISCO, Jan. 11, 2012 /PRNewswire/ -- goBalto, developer of new generation web-based clinical research solutions, announced that it successfully completed a FDA 21 CFR Part 11 compliance audit of its goBalto Tracker™ Software-as-a-Service (SaaS) clinical trials application. Tracker's successful audit will help both sponsors / clinical research organizations and investigator sites running clinical trials comply with FDA rules and regulations governing electronic records and electronic signatures.

"The Tracker application demonstrated compliance with the current 21 CFR Part 11 industry standards feature set for security, data transfer, audit trails, and electronic signatures. No deficiencies were found. The implementation of security and electronic signature components is elegant and sets a new standard for web-based GxP applications," said David Nettleton, principal at Computer System Validation, who conducted the audit.

goBalto and David Nettleton found innovative ways to balance 21 CFR Part 11 compliance requirements with cutting-edge Agile software development practices, facilitating rapid response from the feedback of clinical trial professionals.

About goBalto

goBalto is a developer of new generation web-based solutions that simplify how clinical trials are conducted in the pharmaceutical, biotechnology and medical device industries. Tracker™, launched in June 2011, is the first purpose-built Software-as-a-Service clinical research tool that enables clinical trials sponsors and clinical research organizations to collaborate with multiple partners directly from the web in a transparent and regulatory compliant manner. Founded in Silicon Valley in 2008 by biotechnology industry veteran Jae Chung and backed by leading health technology investors, goBalto applies Agile and lean startup methodologies to building technological solutions that address evolving global healthcare. Visit www.gobalto.com for more information.

About David Nettleton:

David Nettleton, principal at Computer System Validation, is an industry leader, author, and teacher for 21 CFR Part 11, Annex 11, HIPAA, software validation, and computer system validation. He is involved with the development, purchase, installation, operation and maintenance of computerized systems used in FDA compliant applications. His most popular book is Risk Based Software Validation – Ten easy Steps (Davis Horwood International and PDA – www.pda.org, 2006), which provides fill-in-the-blank templates for completing a COTS software validation project. He has completed more than 205 mission critical laboratory, clinical, and manufacturing software implementation projects.

 


'/>"/>
SOURCE goBalto
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. goBalto Introduces Web-based Solution to Manage Drug-development Collaborations
2. goBalto Drug Development Partnering WebSite to Include Clinical Trials Support's List of Investigator Sites
3. goBalto Partners with Maya Clinicals to Expand Its List of Investigator Sites
4. MiMedx Group Completes $5,000,000 Private Placement
5. PDL BioPharma Completes Regular Quarterly Dividend Payment
6. CeNeRx BioPharma Completes $4.85 Million Financing
7. Aratana Therapeutics Completes $15 Million Series B Financing
8. InnoPharma Completes $15 Million Series A Financing
9. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
10. Agendia Successfully Completes Bi-Annual FDA Inspection
11. HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):